CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of bladder cancer and renal cell carcinoma.
  
  LEARNING OBJECTIVES

  • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for metastatic renal cell carcinoma (RCC), and develop strategies to appropriately integrate this approach into patient care.
  • Appraise available clinical trial data evaluating recently FDA-approved combinations of anti-PD-1/PD-L1 antibodies with multikinase inhibitors for previously untreated metastatic RCC, and counsel patients about the risks and benefits of these novel regimens.
  • Develop a rational therapeutic approach to the sequencing of systemic therapies for patients with advanced RCC whose disease progresses on first-line treatment, incorporating tyrosine kinase inhibitors, mTOR inhibitors and immunotherapeutic agents.
  • Consider the recent FDA approval of pembrolizumab for high-risk, non-muscle-invasive urothelial bladder carcinoma (UBC) that is unresponsive to BCG, and determine how pembrolizumab can be appropriately integrated into patient care.
  • Evaluate available data and ongoing trials investigating the use of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and refer eligible patients for appropriate study participation.
  • Review available clinical trial data leading to the recent FDA approval of the anti-PD-L1 antibody avelumab as maintenance therapy after first-line chemotherapy for patients with previously untreated metastatic UBC, and optimally incorporate this novel strategy into management algorithms.
  • Assess available and emerging clinical trial data evaluating anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated metastatic UBC, and consider the potential role of this approach in routine practice.
  • Recognize the FDA approval of erdafitinib for advanced UBC with susceptible FGFR3 or FGFR2 genetic alterations in patients whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
  • Recall the mechanism of action and pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Sumanta K Pal, MD
  Clinical Professor, Department of Medical Oncology
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  No financial interests or affiliations to disclose.
  
  David I Quinn, MBBS, PhD
  Medical Director, USC Norris Cancer Hospital and Clinics
  Head, Section of GU Cancer, Division of Oncology
  Associate Professor of Medicine
  USC Norris Comprehensive Cancer Center
  Keck School of Medicine of USC
  Los Angeles, California
  
  Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: Eisai Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seagen Inc, Bristol-Myers Squibb Company and Exelixis Inc.
  
  Release date: April 2021
  Expiration date: April 2022